

## M E M O R A N D U M

**To:** Members of the Committee on Financial Services

**From:** FSC Majority Staff

**Date:** July 13, 2017

**Subject:** July 18, 2017 Subcommittee on Capital Markets, Securities, and Investment Hearing Entitled “The Cost of Being a Public Company in Light of Sarbanes-Oxley and the Federalization of Corporate Governance”

---

The Subcommittee on Capital Markets, Securities, and Investment will hold a hearing entitled “The Cost of Being a Public Company in Light of Sarbanes-Oxley and the Federalization of Corporate Governance” on July 18, 2017 at 10:00 a.m. in Room 2128 Rayburn House Office Building. This is a one panel hearing with the following witnesses:

- Thomas Farley, President, NYSE Group
- John Blake, Senior Vice President of Finance, aTyr Pharma, Inc.
- Tom Quaadman, Executive Vice President, Center for Capital Market Competitiveness, U.S. Chamber of Commerce
- J. Robert Brown, Jr., Lawrence W. Treece Professor of Corporate Governance, Director, Corporate & Commercial Law Program, University of Denver Sturm College of Law
- John Berlau, Senior Fellow, Competitive Enterprise Institute

The Subcommittee will conduct an overview of current issues public companies face in light of the Sarbanes-Oxley Act of 2002, which turns 15 years old this month, federal corporate governance mandates, and other factors that may impact a company’s decision to go or remain public. The hearing will examine the benefits, as well as the costs and burdens realized by public companies and the impact that these costs and burdens have on investors and economic growth. The hearing will provide the Subcommittee with the background and foundation to consider legislative proposals to promote capital formation and ease unnecessary regulatory burdens faced by U.S. public companies to ensure that the U.S. capital markets remain the “gold standard” and the preferred venue for companies to raise capital.